The four start-ups in the Business Acceleration Academy are only one week from graduating the three months long BII program, and on May 29 they are pitching to the life science eco-system at the biannual DemoDay.
On the day, the start-ups will receive feedback and be asked questions live on stage by three experienced profiles in life science who form the DemoDay panel:
Patrick M.F. Derkx, Vice President Discovery at Chr. Hansen. Patrick has the global responsibility for early lead development within food cultures, enzymes & AG-bio. He has spent the past 11 years at Chr. Hansen and holds a Ph.D. in biotechnology.
Lene Gerlach, Investment Manager in the Danish Growth Fund. Lene is responsible for life science investments in the early space. She has been the chairman of more than 17 early stage companies, most of them within life sciences, and she has a Ph.D. in neuroscience.
Roger Franklin, Partner in Hadean Ventures. Roger has over a decade of experience in the life science industry in various senior roles within the venture capital, investment banking and strategy consulting sectors. Prior to his business career, Roger specialized in oncology during his doctoral work at Cambridge’s Laboratory of Molecular Biology.
Expectations are high
Panel member Lene Gerlach has high expectations leading up to BII DemoDay.
“I expect to see a well-organized pitch with a good balance between the science and the commercial aspects. Convincing data, intellectual property rights covering their product/technology and validated unique selling points. Finally, a presentation of the team skills and how they consider attaining future needed skills.”
What would be your words of advice for life science start-ups at this very early stage?
Believe in yourself and be persistent because you will meet many ‘NO’s on your way to success. Work hard but make sure to have a work-life-balance that your family can accept.
Do you want to join our DemoDay? Get your ticket here.